A Clear Guide to the Legal Framework
Across Australia, interest in medicinal cannabis has grown steadily over the past decade. Media coverage, international policy shifts, and evolving clinical research have all contributed to increased public awareness.
But awareness is not the same as access — and access, in Australia, is structured carefully within a defined regulatory framework.
If you’re wondering whether doctors can prescribe medicinal cannabis in Australia, the short answer is: yes — under specific legal pathways and clinical oversight.
The longer answer is more nuanced.
The Regulatory Foundation
In Australia, medicinal cannabis products are regulated as therapeutic goods under the Therapeutic Goods Act 1989. Most medicinal cannabis products are classified as Schedule 4 (Prescription Only Medicine) or Schedule 8 (Controlled Drug) under the Poisons Standard.
This means they cannot be advertised directly to the public and are only available through a medical practitioner who is authorised to prescribe within the regulatory framework.
The Therapeutic Goods Administration (TGA) oversees access at a federal level.
You can read the TGA’s overview here:
→ https://www.tga.gov.au/products/medicines/prescription-medicines/medicinal-cannabis
The Two Main Access Pathways
Doctors in Australia may prescribe medicinal cannabis through one of two primary pathways:
1. Special Access Scheme (SAS)
The Special Access Scheme allows medical practitioners to apply to the TGA to prescribe an unapproved therapeutic good for an individual patient, where clinically appropriate.
There are different categories within SAS (including Category B), depending on the clinical circumstances.
More information is available here:
→ https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Under this pathway, the prescribing doctor submits an application outlining clinical justification. If authorised, a prescription may then be issued.
2. Authorised Prescriber Pathway
Some doctors become Authorised Prescribers for specific medicinal cannabis products and clinical indications.
Under this model, once approved, the practitioner can prescribe without submitting an individual application to the TGA each time — provided prescribing remains within the approved scope.
Details are available here:
→ https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
State and Territory Considerations
While the TGA governs federal access, state and territory laws also apply — particularly for Schedule 8 products.
Depending on the jurisdiction (Western Australia, New South Wales, Queensland, etc.), additional approvals or reporting requirements may exist.
For example, prescribing a Schedule 8 medicine may require state health department notification or approval in certain circumstances.
This layered system reflects Australia’s cautious and structured approach to controlled medicines.
What Conditions Can Be Considered?
It is important to understand that medicinal cannabis products are generally unapproved medicines in Australia. This means they have not undergone the same evaluation process as medicines included on the Australian Register of Therapeutic Goods (ARTG).
The TGA does not publish a fixed list of “approved conditions.” Instead, prescribing decisions sit with the treating medical practitioner, who must:
Conduct a thorough clinical assessment
Consider conventional treatment options
Evaluate potential risks and benefits
Determine whether medicinal cannabis may be appropriate in that individual context
Prescribing is therefore not automatic or guaranteed. It is case-by-case and clinically justified.
Advertising Restrictions
Under Australian law, prescription medicines (including most medicinal cannabis products) cannot be advertised to the public.
This includes promotional claims, testimonials, or representations suggesting guaranteed outcomes.
The legal framework is designed to ensure that decisions about prescription medicines occur within a clinical setting — not through marketing. If you see marketing about medicinal cannabis, proceed carefully as there are many scams occuring in the space.
You can read more about advertising restrictions here:
→ https://www.tga.gov.au/how-we-regulate/advertising
The Role of Clinical Assessment
Because medicinal cannabis products are prescription-only and often unapproved goods, structured assessment is central to responsible prescribing.
This may include:
Review of medical history
Assessment of current medications
Consideration of contraindications
Discussion of potential side effects
Ongoing monitoring
In other words, the decision is medical — not transactional.
A System Designed for Oversight
Australia’s approach reflects a balance between access and caution.
The framework:
Recognises evolving research
Maintains prescribing within medical practice
Restricts public advertising
Requires documentation and oversight
For patients exploring options, clarity begins with understanding this structure. Conversations about suitability occur within consultation — where nuance, history, and risk assessment can be properly considered.
Further Reading
Therapeutic Goods Administration – Medicinal Cannabis Overview
https://www.tga.gov.au/products/medicines/prescription-medicines/medicinal-cannabis
Special Access Scheme (SAS) Guidance
https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Authorised Prescriber Scheme
https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
Advertising Therapeutic Goods
https://www.tga.gov.au/how-we-regulate/advertising
If you are seeking general information about how prescription medicines are regulated in Australia, the TGA resources above provide the most up-to-date guidance.
When it comes to individual circumstances, the appropriate starting point is always a discussion with a qualified medical practitioner operating within this regulatory framework.
A Clear Guide to the Legal Framework
Across Australia, interest in medicinal cannabis has grown steadily over the past decade. Media coverage, international policy shifts, and evolving clinical research have all contributed to increased public awareness.
But awareness is not the same as access — and access, in Australia, is structured carefully within a defined regulatory framework.
If you’re wondering whether doctors can prescribe medicinal cannabis in Australia, the short answer is: yes — under specific legal pathways and clinical oversight.
The longer answer is more nuanced.
The Regulatory Foundation
In Australia, medicinal cannabis products are regulated as therapeutic goods under the Therapeutic Goods Act 1989. Most medicinal cannabis products are classified as Schedule 4 (Prescription Only Medicine) or Schedule 8 (Controlled Drug) under the Poisons Standard.
This means they cannot be advertised directly to the public and are only available through a medical practitioner who is authorised to prescribe within the regulatory framework.
The Therapeutic Goods Administration (TGA) oversees access at a federal level.
You can read the TGA’s overview here:
→ https://www.tga.gov.au/products/medicines/prescription-medicines/medicinal-cannabis
The Two Main Access Pathways
Doctors in Australia may prescribe medicinal cannabis through one of two primary pathways:
1. Special Access Scheme (SAS)
The Special Access Scheme allows medical practitioners to apply to the TGA to prescribe an unapproved therapeutic good for an individual patient, where clinically appropriate.
There are different categories within SAS (including Category B), depending on the clinical circumstances.
More information is available here:
→ https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Under this pathway, the prescribing doctor submits an application outlining clinical justification. If authorised, a prescription may then be issued.
2. Authorised Prescriber Pathway
Some doctors become Authorised Prescribers for specific medicinal cannabis products and clinical indications.
Under this model, once approved, the practitioner can prescribe without submitting an individual application to the TGA each time — provided prescribing remains within the approved scope.
Details are available here:
→ https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
State and Territory Considerations
While the TGA governs federal access, state and territory laws also apply — particularly for Schedule 8 products.
Depending on the jurisdiction (Western Australia, New South Wales, Queensland, etc.), additional approvals or reporting requirements may exist.
For example, prescribing a Schedule 8 medicine may require state health department notification or approval in certain circumstances.
This layered system reflects Australia’s cautious and structured approach to controlled medicines.
What Conditions Can Be Considered?
It is important to understand that medicinal cannabis products are generally unapproved medicines in Australia. This means they have not undergone the same evaluation process as medicines included on the Australian Register of Therapeutic Goods (ARTG).
The TGA does not publish a fixed list of “approved conditions.” Instead, prescribing decisions sit with the treating medical practitioner, who must:
Conduct a thorough clinical assessment
Consider conventional treatment options
Evaluate potential risks and benefits
Determine whether medicinal cannabis may be appropriate in that individual context
Prescribing is therefore not automatic or guaranteed. It is case-by-case and clinically justified.
Advertising Restrictions
Under Australian law, prescription medicines (including most medicinal cannabis products) cannot be advertised to the public.
This includes promotional claims, testimonials, or representations suggesting guaranteed outcomes.
The legal framework is designed to ensure that decisions about prescription medicines occur within a clinical setting — not through marketing. If you see marketing about medicinal cannabis, proceed carefully as there are many scams occuring in the space.
You can read more about advertising restrictions here:
→ https://www.tga.gov.au/how-we-regulate/advertising
The Role of Clinical Assessment
Because medicinal cannabis products are prescription-only and often unapproved goods, structured assessment is central to responsible prescribing.
This may include:
Review of medical history
Assessment of current medications
Consideration of contraindications
Discussion of potential side effects
Ongoing monitoring
In other words, the decision is medical — not transactional.
A System Designed for Oversight
Australia’s approach reflects a balance between access and caution.
The framework:
Recognises evolving research
Maintains prescribing within medical practice
Restricts public advertising
Requires documentation and oversight
For patients exploring options, clarity begins with understanding this structure. Conversations about suitability occur within consultation — where nuance, history, and risk assessment can be properly considered.
Further Reading
Therapeutic Goods Administration – Medicinal Cannabis Overview
https://www.tga.gov.au/products/medicines/prescription-medicines/medicinal-cannabis
Special Access Scheme (SAS) Guidance
https://www.tga.gov.au/resources/resource/guidance/special-access-scheme-sas-guidance-health-practitioners
Authorised Prescriber Scheme
https://www.tga.gov.au/resources/resource/guidance/authorised-prescriber-scheme
Advertising Therapeutic Goods
https://www.tga.gov.au/how-we-regulate/advertising
If you are seeking general information about how prescription medicines are regulated in Australia, the TGA resources above provide the most up-to-date guidance.
When it comes to individual circumstances, the appropriate starting point is always a discussion with a qualified medical practitioner operating within this regulatory framework.
